My NCBISign In

Display Settings:

Format

Send to:

Choose Destination

    Eur J Pharmacol. 2006 Apr 24;536(1-2):38-46. Epub 2006 Feb 28.

    Osteogenic actions of the anti-diabetic drug metformin on osteoblasts in culture.

    Cortizo AM, Sedlinsky C, McCarthy AD, Blanco A, Schurman L.

    Cátedra de Bioquímica Patológica, Facultad de Ciencias Exactas, Universidad Nacional de La Plata, 1900 La Plata, and Centro de Endocrinología y Metabolismo, Hospital Francés, Buenos Aires, Argentina. cortizo@biol.unlp.edu.ar

    An association has been previously established between uncompensated diabetes mellitus and the loss of bone mineral density and/or quality. In this study, we evaluated the effects of metformin on the growth and differentiation of osteoblasts in culture. Treatment of two osteoblast-like cells (UMR106 and MC3T3E1) with metformin (25-500 microM) for 24 h led to a dose-dependent increase of cell proliferation. Metformin also promoted osteoblastic differentiation: it increased type-I collagen production in both cell lines and stimulated alkaline phosphatase activity in MC3T3E1 osteoblasts. In addition, metformin markedly increased the formation of nodules of mineralization in 3-week MC3T3E1 cultures. Metformin induced activation and redistribution of phosphorylated extracellular signal-regulated kinase (P-ERK) in a transient manner, and dose-dependently stimulated the expression of endothelial and inducible nitric oxide synthases (e/iNOS). These results show for the first time a direct osteogenic effect of metformin on osteoblasts in culture, which could be mediated by activation/redistribution of ERK-1/2 and induction of e/iNOS.

    PMID: 16564524 [PubMed - indexed for MEDLINE]

    Supplemental Content

    Click here to read
    Write to the Help Desk